Development immunomodulative drug based on the recognition mechanism of viral B-DNA.

我们以前的研究已经发现了新的H2B功能，可以识别非染色体双链DNA(DsDNA)，并诱导抗病毒的天然免疫反应。在目前的研究中，我们通过将IPS-1片段与H_2B片段融合构建了融合蛋白N‘-CARD，并发现N’-CARD可诱导I型干扰素(Type I IFN)的产生。此外，核DNA解旋酶II被鉴定为N‘-CARD相关分子，在N’-CARD介导的天然免疫反应中是必不可少的。此外，N‘-CARD融合蛋白转导结构域(N’-CARD-PTD)是一种新型佐剂的候选分子。因此，目前的研究揭示了细胞质dsDNA的H2B传感机制以及用于疫苗开发的新的佐剂候选。

Previous our data have discovered the novel H2B function to recognize non-chromosomal double stranded DNA (dsDNA), and induce antiviral innate immune response. In current research, we constructed the fusion protein, named as N'-CARD, by fusion of IPS-1 fragment with H2B fragment, and found that N'-CARD induced type I interferons (Type I IFNs) production. In addition, nuclear DNA helicase II was identified as N'-CARD associated molecules, and was indispensable for N'-CARD-mediated innate immune response. Furthermore, N'-CARD fused to protein transduction domain (N'-CARD-PTD) is a candidate of novel adjuvant. Therefore, current research revealed H2B-sensing machinery of cytoplasmic dsDNA as well as novel adjuvant candidate for vaccine development.